Insmed's total inventories for the quarter that ended in Mar. 2024 was $83.0 Mil. Insmed's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $83.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Insmed's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-6.45.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Insmed's Days Inventory for the
three
months ended in Mar. 2024 was 434.39.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Insmed's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.21.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Insmed's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.10.
Insmed Total Inventories Historical Data
The historical data trend for Insmed's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Insmed (NAS:INSM) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Insmed's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Insmed's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Insmed Total Inventories Related Terms
Thank you for viewing the detailed overview of Insmed's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 